EP4452939A4 - Polypodale serotonerge verbindungen und prodrugs von serotoninrezeptoragonisten und antagonisten - Google Patents
Polypodale serotonerge verbindungen und prodrugs von serotoninrezeptoragonisten und antagonistenInfo
- Publication number
- EP4452939A4 EP4452939A4 EP22912515.8A EP22912515A EP4452939A4 EP 4452939 A4 EP4452939 A4 EP 4452939A4 EP 22912515 A EP22912515 A EP 22912515A EP 4452939 A4 EP4452939 A4 EP 4452939A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antagonists
- polypodal
- prodrugs
- serotonin receptor
- serotonergic compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293730P | 2021-12-24 | 2021-12-24 | |
| US202263299817P | 2022-01-14 | 2022-01-14 | |
| US202263338994P | 2022-05-06 | 2022-05-06 | |
| PCT/US2022/053910 WO2023122320A1 (en) | 2021-12-24 | 2022-12-23 | Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4452939A1 EP4452939A1 (de) | 2024-10-30 |
| EP4452939A4 true EP4452939A4 (de) | 2025-12-10 |
Family
ID=86903690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22912515.8A Pending EP4452939A4 (de) | 2021-12-24 | 2022-12-23 | Polypodale serotonerge verbindungen und prodrugs von serotoninrezeptoragonisten und antagonisten |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4452939A4 (de) |
| JP (1) | JP2025500321A (de) |
| WO (1) | WO2023122320A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| US20240158350A1 (en) * | 2022-10-14 | 2024-05-16 | Invyxis, Inc. | Ester analogs of psilocin, processes for the preparation thereof, and methods of use |
| AU2024333534A1 (en) * | 2023-08-25 | 2026-03-12 | Compass Pathfinder Limited | 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl oligomeric derivatives |
| WO2025122513A1 (en) * | 2023-12-04 | 2025-06-12 | Delix Therapeutics, Inc. | Methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines |
| WO2026017869A1 (en) * | 2024-07-19 | 2026-01-22 | Compass Pathfinder Limited | Subcutaneous formulations comprising psilocybin derivatives |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996026923A1 (fr) * | 1995-03-02 | 1996-09-06 | Pierre Fabre Medicament | Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments |
| WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| WO2023173227A1 (en) * | 2022-03-18 | 2023-09-21 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| WO2024026574A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| WO2024081961A2 (en) * | 2022-10-14 | 2024-04-18 | Invyxis, Inc. | Ester analogs of psilocin, processes for the preparation thereof, and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201509370UA (en) * | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
| CN110740728A (zh) * | 2017-02-09 | 2020-01-31 | 卡马技术有限责任公司 | 包含裸头草碱衍生物的组合物和方法 |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| CN120904096A (zh) * | 2020-08-21 | 2025-11-07 | 指南针探路者有限公司 | 具有前药特性的新型脱磷酸裸盖菇素衍生物 |
-
2022
- 2022-12-23 EP EP22912515.8A patent/EP4452939A4/de active Pending
- 2022-12-23 WO PCT/US2022/053910 patent/WO2023122320A1/en not_active Ceased
- 2022-12-23 JP JP2024537118A patent/JP2025500321A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996026923A1 (fr) * | 1995-03-02 | 1996-09-06 | Pierre Fabre Medicament | Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments |
| WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| WO2023173227A1 (en) * | 2022-03-18 | 2023-09-21 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| WO2024026574A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| WO2024081961A2 (en) * | 2022-10-14 | 2024-04-18 | Invyxis, Inc. | Ester analogs of psilocin, processes for the preparation thereof, and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025500321A (ja) | 2025-01-09 |
| WO2023122320A1 (en) | 2023-06-29 |
| EP4452939A1 (de) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4452939A4 (de) | Polypodale serotonerge verbindungen und prodrugs von serotoninrezeptoragonisten und antagonisten | |
| EP3478283A4 (de) | Verwendung von neurokinin-1-antagonisten zur behandlung verschiedener pruriginöser störungen | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| EP4081525C0 (de) | Antagonisten des spirocyclischen piperidinmelanocortinsubtyp-2-rezeptors (mc2r) und deren verwendungen | |
| EP4143305A4 (de) | Manipulierte zusammensetzungen des zentralen nervensystems | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| PE20190913A1 (es) | Derivados aromaticos de sulfonamida | |
| DK3407889T3 (da) | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet | |
| CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
| MX391031B (es) | Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa. | |
| EP3912975A4 (de) | Lysophosphatidsäure-rezeptor-antagonisten und herstellungsverfahren dafür | |
| ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
| EA201691167A1 (ru) | Аналоги кортистатина, их синтез и применения | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| DOP2011000326A (es) | Compuestos de n-fenil-(piperazinil u homopiperazinil)- bencensulfonamida o bencensulfonil-fenil-(pipezina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| CO6511237A2 (es) | Dihidrobenzocicloalquiloximetl-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas | |
| EP3525779C0 (de) | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone | |
| EA201691413A1 (ru) | Селективные антагонисты nr2b | |
| EP4208446A4 (de) | Nitrierte psilocybinderivate und verwendung davon zur modulation des 5-ht2a-rezeptors und zur behandlung einer psychiatrischen erkrankung | |
| EA201890695A1 (ru) | Новые пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств | |
| NZ730334A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| DK4161927T3 (da) | Spiroforbindelser som melanocortin-4-receptorantagonister og anvendelser deraf | |
| EA201890448A1 (ru) | Фумагиллиновые спироциклические соединения и конденсированные бициклические соединения и способы их получения и применения | |
| AR104837A1 (es) | Compuestos heterocíclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de nmda nr2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240702 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20251110 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 209/16 20060101AFI20251104BHEP Ipc: C07D 401/14 20060101ALI20251104BHEP Ipc: C07D 401/12 20060101ALI20251104BHEP Ipc: C07D 413/12 20060101ALI20251104BHEP Ipc: C07D 403/06 20060101ALI20251104BHEP Ipc: A61K 31/4045 20060101ALI20251104BHEP Ipc: A61P 25/22 20060101ALI20251104BHEP |